Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects

Glodzik, Lidia; Rusinek, Henry; Kamer, Angela R.; Pirraglia, Elizabeth; Tsui, Wai; Mosconi, Lisa; Yi, Li; McHugh, Pauline; Murray, John D.; Williams, Schantel; Osorio, Ricardo S.; Randall, Catherine; Butler, Tracy; Deshpande, Anup; Vallabhajolusa, Shankar; Leon, Mony J. de

doi:10.1016/j.dadm.2016.02.007

Cited by 26 publications

(25 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study assesses a large pathologic series of FTD syndromes without AD and reports Ab deposition in 38% (21/56) in patients with bvFTD, 37% (14/38) in patients with PPA, and 57% (8/14) in age-matched controls. The presence and topographical progression of Ab increased with age in FTD, as observed in controls [23,24]. In particular, our results are consistent with recent results showing that the transition to amyloidosis in the population without substantive neurodegeneration is greatest between 60 and 75 years of age [25].…”

Section: Discussionsupporting

confidence: 92%

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes

Tan

Kril

Yang

et al. 2017

Alz & Dem Diag Ass & Dis Mo

View full text Add to dashboard Cite

IntroductionThe diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes.MethodsAβ was assessed in 98 autopsy-confirmed FTD and 36 control cases, and the pathological accuracy of 11C-Pittsburgh compound B (PiB)–positron emission tomography imaging was assessed in a subset of FTD cases (n = 15).ResultsAβ was identified in a similar proportion of FTD syndromes and age-matched controls and increases with age. Alzheimer's disease pathology was identified in all cases with high PiB retention and in one case with low PiB retention. We further demonstrate a strong regional correlation between volume fraction of histological Aβ with PiB standard uptake value ratio scaled to the white matter.DiscussionThe present study provides a pathologic reference to assist in the interpretation of in vivo assessments in FTD syndromes.

show abstract

Section: Discussionsupporting

confidence: 92%

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes

Tan

Kril

Yang

et al. 2017

Alz & Dem Diag Ass & Dis Mo

View full text Add to dashboard Cite

show abstract

“…In fact, a recent statement by the World Dementia Council suggested that "Regular physical activity and management of cardiovascular risk factors (e.g., diabetes, obesity, smoking, and hypertension) are associated with a reduced risk of cognitive decline and may reduce the risk of dementia" [288,289]. A recent cross-sectional study concluded that the use of certain medications to treat vascular disease, especially angiotensin receptor blockers and diuretics, may decrease Ab accumulation [290]. In a recent review, Deckers et al (2015) [291] found that the most common modifiable risk factors for AD development included hypertension, diabetes, midlife obesity, physical inactivity, hyperlipidemia, and smoking.…”

Section: Discussionmentioning

confidence: 99%

Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis

Santos

Snyder

et al. 2017

Alz & Dem Diag Ass & Dis Mo

325

263

View full text Add to dashboard Cite

As the population ages due to demographic trends and gains in life expectancy, the incidence and prevalence of dementia increases, and the need to understand the etiology and pathogenesis of dementia becomes ever more urgent. Alzheimer's disease (AD), the most common form of dementia, is a complex disease, the mechanisms of which are poorly understood. The more we learn about AD, the more questions are raised about our current conceptual models of disease. In the absence of a cure or the means by which to slow disease progress, it may be prudent to apply our current knowledge of the intersection between AD, cardiovascular disease, and cerebrovascular disease to foster efforts to delay or slow the onset of AD. This review discusses our current understanding of the epidemiology, genetics, and pathophysiology of AD, the intersection between AD and vascular causes of dementia, and proposes future directions for research and prevention.

show abstract

“…A growing body of literature suggests that the vascular risk factors comprising MetS are associated with Aβ accumulation. Specifically, amyloid deposition has been associated with obesity [12], diabetes [13], cholesterol levels [14, 15], and hypertension [16, 17]. Though multiple review articles highlight the disruption in Aβ metabolism as a potential link between the development of MetS and AD [18, 19], the neuropathological association between MetS and cerebral Aβ has not been fully explored.…”

Section: Introductionmentioning

confidence: 99%

Metabolic Syndrome and Amyloid Accumulation in the Aging Brain

Gómez

Beason‐Held

Bilgel

et al. 2018

JAD

View full text Add to dashboard Cite

Background: Recent studies show links between metabolic syndrome and Alzheimer’s disease (AD) neuropathology. Understanding the link between vascular-related health conditions and dementia will help target at risk populations and inform clinical strategies for early detection and prevention of AD. Objective: To determine whether metabolic syndrome is associated with global cerebral amyloid-β (Aβ) positivity and longitudinal Aβ accumulation. Methods: Prospective study of 165 participants who underwent (11)C-Pittsburgh compound B (PiB) PET neuroimaging to measure Aβ, from June 2005 to May 2016. Metabolic syndrome was defined using the revised Third Adults Treatment Panel of the National Cholesterol Education Program criteria. Participants were classified as PiB+/−. Linear mixed effects models assessed the relationships between baseline metabolic syndrome and PiB status and regional Aβ change over time. Results: A total of 165 cognitively normal participants of the Baltimore Longitudinal Study of Aging (BLSA) Neuroimaging substudy, aged 55–92 years (mean baseline age = 76.4 years, 85 participants were male), received an average of 2.5 PET-PiB scans over an average interval of 2.6 (3.08 SD) years between first and last visits. Metabolic syndrome was not associated with baseline PiB positivity or concurrent regional Aβ. Metabolic syndrome was associated with increased rates of Aβ accumulation in superior parietal and precuneus regions over time in the PiB+ group. Elevated fasting glucose and blood pressure showed individual associations with accelerated Aβ accumulation. Conclusion: Metabolic syndrome was associated with accelerated Aβ accumulation in PiB+ individuals and may be an important factor in the progression of AD pathology.

show abstract

Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects

Cited by 26 publications

References 52 publications

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes

Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis

Metabolic Syndrome and Amyloid Accumulation in the Aging Brain

Contact Info

Product

Resources

About